Dr. Andrew Cavey

Chief Executive Officer ITM Group

Dr. Andrew Cavey will join ITM as Chief Executive Officer from September 1, 2024 to lead the company, already a bedrock of the radiopharmaceutical industry, as it grows and furthers its leadership in Radiopharmaceutical Therapy innovation.

Andrew is a physician and an experienced healthcare executive, with expertise and a successful track record in radiopharmaceutical drug development and commercialization across leading global biopharmaceutical organizations. He will help guide ITM’s continued progress in its pipeline and radioisotope manufacturing capacities.

Before joining ITM, Andrew was SVP, Head of Global Program Leaders, Hematology, Oncology, Cell Therapy at Bristol Myers Squibb. Over the course of his career, he has also held a number of corporate strategy, commercial and drug development leadership roles at Novartis culminating in his role as Global Program Head, Prostate Cancer, in which he co-led the company’s Radiopharmaceutical Therapy strategy and led teams overseeing the clinical development and regulatory approvals of radiopharmaceuticals in the US and Europe. In his early career, he practiced medicine as a physician in the UK’s NHS, and worked as a humanitarian aid worker for various non-governmental organizations in sub-Saharan Africa and South Asia.

Andrew holds physiological sciences and medical degrees from Oxford University, and a Master’s in Public Health from Harvard University. He gained membership to the UK Royal College of Physicians and currently serves as a Board Trustee for Parkinson's UK. He is married and has three children.